The Phase IIb trial is anticipated to enroll about 400 treatment-naive, genotype-1 or genotype 4 hepatitis C virus (HCV)-infected patients. The trial will evaluate the dose and duration
As a result of the designation, a new drug application (NDA) for Soliris would receive priority review from the Japanese regulatory authorities once it is submitted, and the
Clarus Ventures, a life sciences venture capital firm, led the round and was joined with a follow-on investment by FatBoy Capital. In conjunction with the financing, Kurt Wheeler
Under the terms of the agreement, current International Bio Immune Systems (IBS) shareholders will have the opportunity to become shareholders in Neogenix. Additional terms of the transaction have
Enrollment is now closed in this study to assess the safety and efficacy of Augment for the treatment of foot and ankle fusions as compared to autograft, the
According to BioSeek, under the collaboration, it will, over the next year, both carry out broad-based profiling of selected UCB new chemical and biological entities, and guide lead
Chiome and Chugai will develop novel value-added therapeutic monoclonal antibodies employing Chiome’s autonomously diversifying library (ADLib) system and will apply the system to assessment of target proteins and
The study, which is underway in Canada, has recruited 120 patients with confirmed cat allergies, and all the participants have completed screening and initial dosing with none experiencing
The acquired hematology business will continue to operate under the name Biocode Hycel, which has operations near Rennes, France. The business will be vertically integrated into Escalon’s clinical
Galapagos has also reached milestones on other compounds in the alliance, triggering payments totaling E7.6 million to Galapagos. To date, Galapagos has earned a total of E25.5 million
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.